ContraFect - CFRX Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ContraFect in the last year. There are currently 3 hold ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" CFRX shares.
View CFRX analyst ratings or view top-rated stocks.

4 analysts have issued 12 month price targets for ContraFect's shares. Their CFRX share price forecasts range from $1.00 to $7.00. On average, they expect the company's share price to reach $3.00 in the next year. This suggests a possible upside of 3,057.9% from the stock's current price.
View analysts price targets for CFRX or view top-rated stocks among Wall Street analysts.

ContraFect's stock was trading at $0.0960 at the beginning of the year. Since then, CFRX stock has decreased by 1.0% and is now trading at $0.0950.
View the best growth stocks for 2023 here.

ContraFect saw a increase in short interest during the month of January. As of January 15th, there was short interest totaling 1,050,000 shares, an increase of 153.4% from the December 31st total of 414,300 shares. Based on an average daily volume of 6,130,000 shares, the days-to-cover ratio is currently 0.2 days.
View ContraFect's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 23rd 2023.
View our CFRX earnings forecast.

ContraFect Co. (NASDAQ:CFRX) released its quarterly earnings results on Monday, November, 14th. The biotechnology company reported ($0.43) earnings per share for the quarter, missing analysts' consensus estimates of ($0.23) by $0.20.

Shares of ContraFect reverse split on Tuesday, February 4th 2020. The 1-10 reverse split was announced on Tuesday, February 4th 2020. The number of shares owned by shareholders was adjusted after the market closes on Monday, February 3rd 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other ContraFect investors own include SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Verastem (VSTM), Vaxart (VXRT), Matinas BioPharma (MTNB), VBI Vaccines (VBIV), Novavax (NVAX), Cidara Therapeutics (CDTX), Gilead Sciences (GILD) and Dynavax Technologies (DVAX).

ContraFect trades on the NASDAQ under the ticker symbol "CFRX."

ContraFect's stock is owned by a number of institutional and retail investors. Top institutional investors include FNY Investment Advisers LLC (0.00%).
View institutional ownership trends.

Shares of CFRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CFRX stock can currently be purchased for approximately $0.10.

ContraFect (NASDAQ:CFRX) has a market capitalization of $4.15 million. The biotechnology company earns $-20,280,000.00 in net income (profit) each year or ($1.51) on an earnings per share basis.

ContraFect's mailing address is 28 WELLS AVENUE 3RD FLOOR, YONKERS NY, 10701. The official website for the company is www.contrafect.com. The biotechnology company can be reached via phone at (914) 207-2300 or via email at mmessinger@contrafect.com.